- Home
- CIVI vs PTGX Comparison
CIVI vs PTGX Comparison
Compare CIVI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIVI
- PTGX
- Stock Information
- Founded
- CIVI 1999
- PTGX 2006
- Country
- CIVI United States
- PTGX United States
- Employees
- CIVI N/A
- PTGX N/A
- Industry
- CIVI Oil & Gas Production
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CIVI Energy
- PTGX Health Care
- Exchange
- CIVI Nasdaq
- PTGX Nasdaq
- Market Cap
- CIVI 2.5B
- PTGX 2.9B
- IPO Year
- CIVI 2011
- PTGX 2016
- Fundamental
- Price
- CIVI $32.39
- PTGX $53.34
- Analyst Decision
- CIVI Buy
- PTGX Strong Buy
- Analyst Count
- CIVI 12
- PTGX 9
- Target Price
- CIVI $49.60
- PTGX $67.11
- AVG Volume (30 Days)
- CIVI 2.3M
- PTGX 898.5K
- Earning Date
- CIVI 07-31-2025
- PTGX 08-05-2025
- Dividend Yield
- CIVI 6.17%
- PTGX N/A
- EPS Growth
- CIVI 5.61
- PTGX N/A
- EPS
- CIVI 8.73
- PTGX 0.86
- Revenue
- CIVI $5,071,808,000.00
- PTGX $207,801,000.00
- Revenue This Year
- CIVI N/A
- PTGX N/A
- Revenue Next Year
- CIVI N/A
- PTGX $47.15
- P/E Ratio
- CIVI $3.71
- PTGX $62.27
- Revenue Growth
- CIVI 22.15
- PTGX N/A
- 52 Week Low
- CIVI $22.79
- PTGX $30.67
- 52 Week High
- CIVI $74.04
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- CIVI 60.80
- PTGX 58.33
- Support Level
- CIVI $31.94
- PTGX $54.48
- Resistance Level
- CIVI $34.25
- PTGX $57.18
- Average True Range (ATR)
- CIVI 1.48
- PTGX 2.04
- MACD
- CIVI 0.43
- PTGX -0.09
- Stochastic Oscillator
- CIVI 74.97
- PTGX 57.13
About CIVI Civitas Resources Inc.
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.